trending Market Intelligence /marketintelligence/en/news-insights/trending/VRogTH3Q7hR0SGbRrUHWJA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bayer removes nearly all Essure birth control devices from US market

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bayer removes nearly all Essure birth control devices from US market

Bayer AG has recovered over 99% of unused Essure birth control devices that were to be pulled from the U.S. market in 2018 amid reports of serious health risks to women who received the devices, the U.S. Food and Drug Administration said in a Jan. 10 update.

Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, said monitoring women with Essure devices continues to be a top priority for the agency, and the devices will no longer be available for implantation in the U.S. Bayer is actively seeking 10 remaining unused devices, Shuren said.

Essure is associated with serious health risks including persistent pain, bleeding of the uterus and migration of the device's coils into the pelvis or abdomen.

The FDA first asked the German drugmaker to conduct a post-market trial for Essure in 2016. The U.S. regulator revised the study requirements in December 2018 to add blood testing of women enrolled during follow-up visits and extend the duration of the trial to five years from three. The enrollment period for the post-market study is complete, with 340 women choosing Essure instead of a surgical birth control option, the agency said.

Essure, approved in 2002 as a permanent birth control device for women, can be implanted without requiring a surgical incision.